Eupraxia Pharmaceuticals Inc.
EPRX
$8.08
-$0.17-2.06%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 10.77% | -42.34% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 13.45% | -1.27% | |||
| Operating Income | -13.45% | 1.27% | |||
| Income Before Tax | -14.42% | 24.35% | |||
| Income Tax Expenses | 118.71% | 23.01% | |||
| Earnings from Continuing Operations | -14.53% | 24.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 364.29% | -86.14% | |||
| Net Income | -14.49% | 24.28% | |||
| EBIT | -13.45% | 1.27% | |||
| EBITDA | -13.38% | 1.31% | |||
| EPS Basic | 2.57% | 30.81% | |||
| Normalized Basic EPS | 2.08% | 31.51% | |||
| EPS Diluted | 2.57% | 30.81% | |||
| Normalized Diluted EPS | 2.08% | 31.51% | |||
| Average Basic Shares Outstanding | 16.77% | 10.56% | |||
| Average Diluted Shares Outstanding | 16.77% | 10.56% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||